SCHEMBL3214643

SCHEMBL3214643

COc1ccc(C=CC(=O)CC(=O)C=Cc2ccc(OC)cc2OC)c(OC)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.80
MAPT P10636 9/20 0.77
ALDH1A1 P00352 3/20 0.77
MEN1 O00255 3/20 0.77
KMT2A Q03164 3/20 0.77
LY96 Q9Y6Y9 1/20 0.74
APP P05067 4/20 0.72
TNFRSF1A P19438 1/20 0.68
CYP1A1 P04798 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP1B1 Q16678 1/20 0.66
NPC1 O15118 2/20 0.65
RAB9A P51151 2/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
NFE2L2 Q16236 1/20 0.64
MAPK1 P28482 2/20 0.63
HPGD P15428 2/20 0.62
LMNA P02545 1/20 0.62
CHRNA7 P36544 1/20 0.60
KDM4E B2RXH2 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3214610 1.00 BACE1 (0.80) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3204166 0.89 BACE1 (1.00) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3204181 0.89 BACE1 (1.00) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3209236 0.87 JUN (0.77) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL8686650 0.87 MAPT (0.77) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL7959387 0.87 MAPT (0.77) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3209264 0.87 JUN (0.77) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3210960 0.87 APP (0.86) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3210991 0.87 APP (0.86) BACE1MAPTALDH1A1MEN1KMT2A
SCHEMBL3200717 0.87 BACE1 (0.80) BACE1MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371263-B2 Protective effects of curcumin against hemorrhagic stroke injury AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2016-06-21 US disclosed
US-9371263-B2 Protective effects of curcumin against hemorrhagic stroke injury AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2016-06-21 US disclosed
US-20150087705-A1 Protective Effects of Curcumin Against Hemorrhagic Stroke Injury AUGUSTA UNIVERSITY 2015-03-26 US disclosed
US-20150087705-A1 Protective Effects of Curcumin Against Hemorrhagic Stroke Injury AUGUSTA UNIVERSITY 2015-03-26 US disclosed
US-8962674-B2 Curcumin derivative TOKYO INSTITUTE OF TECHNOLOGY (JP) 2015-02-24 US disclosed
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE TOKYO INSTITUTE OF TECHNOLOGY (JP) 2010-02-25 US disclosed
EP-2123637-A1 NOVEL CURCUMIN DERIVATIVE Tokyo Institute of Technology (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE BACE1, APP, BACE2 BACE1 1/4885MAPT 8/4885ALDH1A1 253/4885
US-20150087705-A1 Protective Effects of Curcumin Against Hemorrhagic Stroke Injury NFKBIA, AP1G1, NFRKB BACE1 532/4885MAPT 1629/4885ALDH1A1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.